{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:39:49Z","timestamp":1791290389100,"version":"4.3.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01303-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:05:33Z","timestamp":1773324333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)"],"prefix":"10.1038","volume":"6","author":[{"given":"Da-Long","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Liang","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Quan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Rong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Meng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-He","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Shuang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-Jian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Gao","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Mei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-De","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1494-6396","authenticated-orcid":false,"given":"Jian-Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the GUIDANCE investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-De","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Long","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Liang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Liang","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-He","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Bing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan-Jian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Sheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Rong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Quan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Meng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Shuang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Cai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Kai","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Cong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"1303_CR1","doi-asserted-by":"publisher","first-page":"18296","DOI":"10.18632\/oncotarget.15433","volume":"8","author":"JH Zhong","year":"2017","unstructured":"Zhong, J. H. et al. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: a real-world study. Oncotarget 8, 18296\u201318302 (2017).","journal-title":"Oncotarget"},{"key":"1303_CR2","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 35, 2155\u20132166 (2015).","journal-title":"Liver Int."},{"key":"1303_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000530495","volume":"12","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition). Liver Cancer 12, 405\u2013444 (2023).","journal-title":"Liver Cancer"},{"key":"1303_CR4","doi-asserted-by":"crossref","unstructured":"Zhong, J. H. et al. Intermediate-stage HCC\u2013upfront resection can be feasible. Nat. Rev. Clin. Oncol. 12, 295 (2015).","DOI":"10.1038\/nrclinonc.2014.122-c3"},{"key":"1303_CR5","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol. 82, 315\u2013374 (2025).","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"1303_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"1303_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/gutjnl-2014-308139","volume":"64","author":"JH Zhong","year":"2015","unstructured":"Zhong, J. H., Ke, Y., Wang, Y. Y. & Li, L. Q. Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension. Gut 64, 520\u2013521 (2015).","journal-title":"Gut"},{"key":"1303_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","volume":"260","author":"JH Zhong","year":"2014","unstructured":"Zhong, J. H. et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann. Surg. 260, 329\u2013340 (2014).","journal-title":"Ann. Surg."},{"key":"1303_CR9","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","volume":"65","author":"T Kokudo","year":"2016","unstructured":"Kokudo, T. et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J. Hepatol. 65, 938\u2013943 (2016).","journal-title":"J. Hepatol."},{"key":"1303_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000515554","volume":"10","author":"R Govalan","year":"2021","unstructured":"Govalan, R. et al. Comparison of surgical resection and systemic treatment for hepatocellular carcinoma with vascular invasion: National Cancer Database Analysis. Liver Cancer 10, 407\u2013418 (2021).","journal-title":"Liver Cancer"},{"key":"1303_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa, K. et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol. Res. 53, 383\u2013390 (2023).","journal-title":"Hepatol. Res."},{"key":"1303_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J. Hepatol. 76, 681\u2013693 (2022).","journal-title":"J. Hepatol."},{"key":"1303_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/SLA.0b013e3181961c16","volume":"249","author":"WP Zhou","year":"2009","unstructured":"Zhou, W. P. et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann. Surg. 249, 195\u2013202 (2009).","journal-title":"Ann. Surg."},{"key":"1303_CR14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1478-3231.2009.02166.x","volume":"30","author":"TC Chua","year":"2010","unstructured":"Chua, T. C. et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 30, 166\u2013174 (2010).","journal-title":"Liver Int."},{"key":"1303_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron, T. U. et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 219\u2013229 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb, A. O. et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 208\u2013218 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1303_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet, J. M. et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 21, 294\u2013311 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1303_CR18","doi-asserted-by":"crossref","unstructured":"Vogel, A. et al. Adjuvant and neoadjuvant therapies for hepatocellular carcinoma. Hepatology 82, 777\u2013793 (2025).","DOI":"10.1097\/HEP.0000000000000726"},{"key":"1303_CR19","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1200\/JCO.2024.42.23_suppl.65","volume":"42","author":"Masatoshi Kudo","year":"2024","unstructured":"Kudo, M. et al. Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with\/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma. J. Clin. Oncol. 42, 4122 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1303_CR20","doi-asserted-by":"publisher","first-page":"S1229","DOI":"10.1016\/j.annonc.2024.08.2277","volume":"35","author":"J Llovet","year":"2024","unstructured":"Llovet, J. et al. LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study. Ann. Oncol. 35, S1229 (2024).","journal-title":"Ann. Oncol."},{"key":"1303_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/HEP.0000000000001229","volume":"82","author":"DL Yang","year":"2025","unstructured":"Yang, D. L. et al. Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages. Hepatology 82, 357\u2013369 (2025).","journal-title":"Hepatology"},{"key":"1303_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. Jama 310, 2191\u20132194 (2013).","journal-title":"Jama"},{"key":"1303_CR23","unstructured":"Yang, D. L. et al. Survival benefit of hepatectomy after complete or partial response to conversion therapy in unresectable hepatocellular carcinoma (GUIDANCE003): a multicenter study. Liver Cancer 14, 687\u2013703 (2025)."},{"key":"1303_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101587","volume":"7","author":"DL Yang","year":"2025","unstructured":"Yang, D. L. et al. Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004). JHEP Rep. 7, 101587 (2025).","journal-title":"JHEP Rep."},{"key":"1303_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1303_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000488035","volume":"7","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer 7, 235\u2013260 (2018).","journal-title":"Liver Cancer"},{"key":"1303_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00274-z","volume":"9","author":"C Huang","year":"2021","unstructured":"Huang, C. et al. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark. Res. 9, 19 (2021).","journal-title":"Biomark. Res."},{"key":"1303_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.21037\/hbsn-21-328","volume":"11","author":"HC Sun","year":"2022","unstructured":"Sun, H. C. et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobil. Surg. Nutr. 11, 227\u2013252 (2022).","journal-title":"Hepatobil. Surg. Nutr."},{"key":"1303_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet, J. M. & Lencioni, R. mRECIST for HCC: performance and novel refinements. J. Hepatol. 72, 288\u2013306 (2020).","journal-title":"J. Hepatol."},{"key":"1303_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07742-x","volume":"25","author":"LX Pan","year":"2024","unstructured":"Pan, L. X. et al. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial. Trials 25, 25 (2024).","journal-title":"Trials"},{"key":"1303_CR31","first-page":"0","volume":"13","author":"K Akahoshi","year":"2024","unstructured":"Akahoshi, K. et al. Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023. Liver Cancer 13, 0\u201310 (2024).","journal-title":"Liver Cancer"},{"key":"1303_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000004346","volume":"272","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras, D. I. et al. Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the Milan criteria. Ann. Surg. 272, 574\u2013581 (2020).","journal-title":"Ann. Surg."},{"key":"1303_CR33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00535-023-02018-2","volume":"58","author":"L Li","year":"2023","unstructured":"Li, L. et al. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study. J. Gastroenterol. 58, 1043\u20131054 (2023).","journal-title":"J. Gastroenterol."},{"key":"1303_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.14218\/JCTH.2024.00030","volume":"12","author":"L Li","year":"2024","unstructured":"Li, L. et al. Adjuvant therapy for hepatocellular carcinoma after curative treatment: several unanswered questions. J. Clin. Transl. Hepatol. 12, 525\u2013533 (2024).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"1303_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/bjs\/znab340","volume":"109","author":"JH Zhong","year":"2022","unstructured":"Zhong, J. H. et al. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study. Br. J. Surg. 109, 71\u201378 (2021).","journal-title":"Br. J. Surg."},{"key":"1303_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205\u2013213 (2004).","journal-title":"Ann. Surg."},{"key":"1303_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/01.sla.0000189131.90876.9e","volume":"242","author":"S Balzan","year":"2005","unstructured":"Balzan, S. et al. The \u201c50-50 criteria\u201d on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann. Surg. 242, 824\u2013828 (2005).","journal-title":"Ann. Surg."},{"key":"1303_CR38","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"1303_CR39","doi-asserted-by":"crossref","unstructured":"Scheiner, B. et al. Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy. Hepatology 81, 1714\u20131727 (2025).","DOI":"10.1097\/HEP.0000000000001163"},{"key":"1303_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo, M. et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 405, 203\u2013215 (2025).","journal-title":"Lancet"},{"key":"1303_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 405, 216\u2013232 (2025).","journal-title":"Lancet"},{"key":"1303_CR42","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.18.02184","volume":"37","author":"X Wei","year":"2019","unstructured":"Wei, X. et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J. Clin. Oncol. 37, 2141\u20132151 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1303_CR43","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1245\/s10434-022-12530-z","volume":"30","author":"XD Zhu","year":"2023","unstructured":"Zhu, X. D. et al. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma. Ann. Surg. Oncol. 30, 2782\u20132790 (2023).","journal-title":"Ann. Surg. Oncol."},{"key":"1303_CR44","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1002\/hep.30490","volume":"69","author":"XP Zhang","year":"2019","unstructured":"Zhang, X. P. et al. An Eastern Hepatobiliary Surgery Hospital\/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study. Hepatology 69, 2076\u20132090 (2019).","journal-title":"Hepatology"},{"key":"1303_CR45","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ejso.2006.04.002","volume":"32","author":"A Sasaki","year":"2006","unstructured":"Sasaki, A. et al. Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur. J. Surg. Oncol. 32, 773\u2013779 (2006).","journal-title":"Eur. J. Surg. Oncol."},{"key":"1303_CR46","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s12072-019-09981-0","volume":"13","author":"C Li","year":"2019","unstructured":"Li, C. et al. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (\u226510 cm): a multicenter propensity matching analysis. Hepatol. Int 13, 736\u2013747 (2019).","journal-title":"Hepatol. Int"},{"key":"1303_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.iliver.2023.08.001","volume":"2","author":"N Badwei","year":"2023","unstructured":"Badwei, N. HCC case management-related challenges: think outside the box!. iLiver 2, 143\u2013145 (2023).","journal-title":"iLiver"},{"key":"1303_CR48","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.iliver.2024.100110","volume":"3","author":"J Xu","year":"2024","unstructured":"Xu, J., Gu, L. & Yang, T. Optimising postoperative surveillance for hepatocellular carcinoma: beyond histological predictors. iLiver 3, 100110 (2024).","journal-title":"iLiver"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01303-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:08:42Z","timestamp":1773328122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01303-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01303-w","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was exempted by the Ethics Committee of Guangxi Medical University Cancer Hospital from the requirement of written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"139"}}